Cambridge based company Mogrify plan to use big data to discover, optimise and commercialise transdifferentiations- generating cells from adult cells without reverting them to a pluripotent state.
But will they be able to play catch up with stem cell therapies have already made it to clinical trials?
-----------------
Check out the audio versions of the Biocast on all your favourite streaming platforms:
Anchor: tiny.cc/3d3ybz
Spotify: tiny.cc/5f3ybz
Google Podcasts: tiny.cc/qj3ybz
Pocket Casts: tiny.cc/jk3ybz
RadioPublic: tiny.cc/sl3ybz
SoundCloud: tiny.cc/xn3ybz
-----------------
Can't get enough of Biotech news? I'll be bringing out more Biocast episodes, so subscribe to keep up to date!
-----------------
Follow me on
LinkedIn: tiny.cc/hoggbz
Facebook: tiny.cc/diggbz
Twitter: tiny.cc/6iggbz
Instagram: tiny.cc/bkggbz
-----------------
Articles around today's news story:
endpts.com/cell-therapy-start...
www.businessweekly.co.uk/news...
www.businesswire.com/news/hom...
www.technologynetworks.com/ce...
www.sciencedirect.com/science...
www.ncbi.nlm.nih.gov/pubmed/2...
31 окт 2019
